American Journal of Clinical Oncology-Cancer Clinical Trials最新文献

{"title":"Adenoid Cystic Carcinoma of the Breast and Adjuvant Radiation Therapy: A Review of Literature.","authors":"Imed Taleb, Sarah Witmeyer, Hélène Charitansky, Sophie Auriol, Camille Chakiba, Nathalie Quenel Tueux, Adeline Petit, Benoite Méry, Wafa Bouleftour, Nicolas Magné","doi":"10.1097/COC.0000000000001194","DOIUrl":"10.1097/COC.0000000000001194","url":null,"abstract":"<p><strong>Objectives: </strong>Adenoid cystic carcinoma (ACC) of the breast is a rare special histologic type of breast cancer. This tumor is classified as low-grade and has a favorable prognosis, with rare occurrence of metastasis and distinctive characteristics. Due to the uncommon nature of this tumor, there are no specific recommendations regarding the therapeutic management of this malignancy. The aim of this review was to provide an overview of breast ACC clinical characteristics with a special focus on radiotherapy management.</p><p><strong>Methods: </strong>A literature review was conducted up to January 2024 through a PubMed search using different combinations of pertinent keywords (eg, Adenoid cystic carcinoma alone, Adenoid cystic carcinoma AND breast Cancer AND radiotherapy; Adenoid cystic carcinoma AND breast cancer AND radiation therapy).</p><p><strong>Results: </strong>This review highlighted the lack of prospective and randomized data guiding treatment algorithms for ACC. Four retrospective studies explored the impact of postoperative radiation and concluded that postoperative radiation contributes to improved survival.</p><p><strong>Conclusions: </strong>Thus, a consideration for radiotherapy indications in ACC of the breast could be further elucidated through prospective randomized studies.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":"392-398"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigator-Assisted Hypofractionation Program Survey Validation for African American Breast Cancer Patients.","authors":"Louisa Onyewadume, Ursula Burnette, Laura E Flores, Shearwood McClelland","doi":"10.1097/COC.0000000000001242","DOIUrl":"https://doi.org/10.1097/COC.0000000000001242","url":null,"abstract":"","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examining the Impact of Social Determinants of Health on Pediatric Central Nervous System Tumor Outcomes Through Medical Record Linkage.","authors":"Seho Park, Scott L Coven, Yvette H Tran, Eneida A Mendonca","doi":"10.1097/COC.0000000000001240","DOIUrl":"https://doi.org/10.1097/COC.0000000000001240","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate how social determinants of health (SDoH) influence health disparities in pediatric central nervous system (CNS) tumor outcomes by integrating individual and community-level data.</p><p><strong>Methods: </strong>Retrospective cohort study. Individual-level electronic health record data from the Indiana Health Information Exchange were linked with community-level data from the Social Assets and Vulnerabilities Indicators using a record linkage method. Associations between CNS tumor diagnoses and SDoH factors were analyzed, as well as the descriptive characteristics of SDoH factors and demographic characteristics of CNS tumor patients.</p><p><strong>Results: </strong>The analysis revealed significant disparities in CNS tumor prevalence and treatment protocols based on SDoH factors. Areas with higher median household income and lower rates of poverty, unemployment, uninsured status, and lack of high school education showed a higher prevalence of CNS-PNET and Meningioma, lower incidence of high-grade glioma, low-grade glioma, and Medulloblastoma. In addition, the use of VP shunts was associated with lower poverty and unemployment rates and higher median household income, whereas Brain Biopsy with Stealth was linked to higher rates of uninsurance, poverty, and lack of a high school diploma.</p><p><strong>Conclusions: </strong>Significant correlations were found between SDoH factors and both CNS tumor outcomes. These findings suggest that integrating community-level SDoH data with individual health records can provide valuable insights and should be leveraged to address health care disparities and improve outcomes in pediatric CNS tumor patients.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACR-ACNM-ARS-SNMMI-SPR Practice Parameter for Treatment of Benign and Malignant Thyroid Disease With I-131 Sodium Iodide.","authors":"Andrew T Trout, Thomas P Boike, Anca M Avram, Parul Barry, Simin Dadparvar, Sai Duriseti, Robert R Flavell, Frederick D Grant, Neha Kwatra, Hollie A Lai, Marguerite T Parisi, Sue S Yom, Mark Tulchinsky, Munir V Ghesani, Rathan M Subramaniam, Terry L Levin, William Small, Naomi R Schechter","doi":"10.1097/COC.0000000000001239","DOIUrl":"https://doi.org/10.1097/COC.0000000000001239","url":null,"abstract":"<p><strong>Objectives: </strong>This practice parameter was developed collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the Society for Pediatric Radiology (SPR). This practice parameter is intended to guide appropriately trained and licensed physicians in the oral administration of I-131 sodium iodide for the treatment of benign and malignant thyroid diseases.</p><p><strong>Methods: </strong>This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters-Nuclear Medicine and Molecular Imaging of the ACR Commissions on Nuclear Medicine and Molecular Imaging, the Committee on Practice Parameters-Radiation Oncology of the ACR Commission on Radiation Oncology, the Committee on Practice Parameters-Pediatric Radiology of the ACR Commission on Pediatric Radiology in collaboration with the ACNM, the ARS, the SNMMI, and the SPR.</p><p><strong>Results: </strong>I-131 sodium iodide is used for the treatment of hyperthyroidism and differentiated thyroid cancer. The therapeutic effect of I-131 sodium iodide is achieved by the emission of ionizing radiation in the form of high-energy beta particles. I-131 sodium iodide therapy requires close cooperation and communication between the clinicians who are responsible for the clinical management of the patient and the physicians who administer radiopharmaceutical therapy. This document provides guidance regarding optimal therapy procedures, appropriate precautions, and therapy in unique situations.</p><p><strong>Conclusions: </strong>This practice parameter is designed to assist practitioners in providing appropriate radiologic care for treating benign and malignant thyroid disease with I-131 sodium iodide.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI Prognostication in Nonsmall Cell Lung Cancer: A Systematic Review.","authors":"Michael Augustin, Kelsey Lyons, Hayeon Kim, David G Kim, Yusung Kim","doi":"10.1097/COC.0000000000001238","DOIUrl":"https://doi.org/10.1097/COC.0000000000001238","url":null,"abstract":"<p><p>The systematic literature review was performed on the use of artificial intelligence (AI) algorithms in nonsmall cell lung cancer (NSCLC) prognostication. Studies were evaluated for the type of input data (histology and whether CT, PET, and MRI were used), cancer therapy intervention, prognosis performance, and comparisons to clinical prognosis systems such as TNM staging. Further comparisons were drawn between different types of AI, such as machine learning (ML) and deep learning (DL). Syntheses of therapeutic interventions and algorithm input modalities were performed for comparison purposes. The review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The initial database identified 3880 results, which were reduced to 513 after the automatic screening, and 309 after the exclusion criteria. The prognostic performance of AI for NSCLC has been investigated using histology and genetic data, and CT, PET, and MR imaging for surgery, immunotherapy, and radiation therapy patients with and without chemotherapy. Studies per therapy intervention were 13 for immunotherapy, 10 for radiotherapy, 14 for surgery, and 34 for other, multiple, or no specific therapy. The results of this systematic review demonstrate that AI-based prognostication methods consistently present higher prognostic performance for NSCLC, especially when directly compared with traditional prognostication techniques such as TNM staging. The use of DL outperforms ML-based prognostication techniques. DL-based prognostication demonstrates the potential for personalized precision cancer therapy as a supplementary decision-making tool. Before it is fully utilized in clinical practice, it is recommended that it be thoroughly validated through well-designed clinical trials.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer: Assessing the Efficacy.","authors":"Jihane Bouziane, Pierre Loap, Sofiane Allali, Laurence Escalup, Jean-Yves Pierga, Youlia Kirova","doi":"10.1097/COC.0000000000001237","DOIUrl":"10.1097/COC.0000000000001237","url":null,"abstract":"<p><p>The combination in patients with HER2-positive and HER2-low metastatic breast cancer (MBC) of Concurrent Trastuzumab Deruxtecan (T-DXd) and Radiation Therapy (RT) is not enough studied. We conducted a retrospective study including patients treated between 11/2020 and 01/2024. Patients with HER2-positive and HER2-low MBC who received concurrent T-DXd and RT were identified. Data on patient demographics, treatment regimens, radiation doses, toxicity profiles, efficacy, and treatment discontinuations were collected. The toxicities were graded using CTCAE V5.0. Population of 33 patients with HER2-positive and HER2-low MBC who underwent concurrent T-DXd&RT, were studied. The median follow-up (FU) was 14 months. There were 39.4 partial remissions and 9.4 attained complete remission. In addition, 39.4% experienced stable disease, and 12.1% faced disease progression necessitating a change in therapy. Safety assessment revealed that acute toxicities were mainly associated with systemic treatment. Survival analysis showed 11 deaths (33.3%) during the FU period, with a median overall survival of 26 months and median progression-free survival of 12 months. The combination of T-DXd with RT in demonstrates promising efficacy with a manageable safety profile. Further studies are warranted to fully elucidate the potential synergistic effects of this treatment regimen and its impact on patient outcome.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric Cancer Mortality in the United States: A Two-Decade Analysis of Trends and Disparities (1999-2020).","authors":"Muzamil Khan, Abu Huraira Bin Gulzar, Fatima Shahid, Belal Hamed Mohamed, Amar Lal, Shree Rath, Nouman Aziz, Waseem Nabi, Anees Cheema, Usama Ali, Adnan Bhat","doi":"10.1097/COC.0000000000001235","DOIUrl":"https://doi.org/10.1097/COC.0000000000001235","url":null,"abstract":"<p><strong>Objectives: </strong>Gastric cancer mortality has declined in recent decades, yet sociodemographic disparities remain. This study analyzed national trends in gastric cancer mortality among US adults, with stratification by demographic and geographic factors.</p><p><strong>Methods: </strong>We examined gastric cancer deaths (ICD-10 C16) in adults aged ≥25 years using CDC WONDER data from 1999 to 2020. Mortality trends were analyzed by age, sex, race/ethnicity, region, and urbanization using joinpoint regression to calculate annual and average annual percent changes (APC, AAPC).</p><p><strong>Results: </strong>From 1999 to 2020, there were 276,023 gastric cancer deaths. Mortality declined more in males (AAPC: -2.97 [95% CI: -3.15 to -2.79]) than females (-2.42 [-2.64 to -2.21]). The largest declines were among Asians (-3.83 [-4.08 to -3.56]) and Blacks (-3.25 [-3.49 to -3.02]), followed by Whites (-2.96 [-3.13 to -2.87]) and Hispanics (-2.31 [-2.58 to -2.06]). Metropolitan areas saw greater declines (-2.72 [-2.83 to -2.62]) than rural areas (-2.41 [-2.68 to -2.12]). By region, the Northeast showed the steepest decline (-3.16 [-3.34 to -2.99]), followed by the Midwest, South, and West. Notably, mortality increased among adults aged 25 to 34 years (AAPC: 0.38 [-1.24 to 2.70]) and 35 to 44 years (0.87 [0.12 to 1.73]).</p><p><strong>Conclusions: </strong>Gastric cancer mortality declined overall but with persistent disparities. Rising rates among younger adults and slower declines in rural and western regions warrant further investigation and targeted interventions.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in Cutaneous T-Cell Lymphoma Treatment: Unveiling Novel Therapeutic Avenues and Clinical Implications.","authors":"Zaheer Qureshi, Abdur Jamil, Fatima Hameed, Navkirat Kahlon","doi":"10.1097/COC.0000000000001230","DOIUrl":"https://doi.org/10.1097/COC.0000000000001230","url":null,"abstract":"<p><strong>Objectives: </strong>The non-Hodgkin lymphoma class known as cutaneous T-cell lymphomas (CTCLs) is uncommon and diverse, mainly affecting the skin. The prognosis is dismal, and despite recent breakthroughs, few treatment options are available for advanced-stage disease. This narrative review outlines the current state of care for CTCLs, emphasizing innovative immunotherapies, targeted medicines, combination approaches, and epigenetic modifiers.</p><p><strong>Methods: </strong>This paper was conducted to summarize the newer approaches to treating CTCL, with a literature search spanning PubMed, Science Direct, and Cochrane databases that identified articles reporting emerging treatments. Selected articles were categorized into sections to summarize pertinent results in a narrative report.</p><p><strong>Results: </strong>Extracorporeal photopheresis with mogamulizumab, a monoclonal antibody targeting CCR4, has shown promise in treating skin and blood involvement while maintaining a good safety record. Additional treatments that have been highlighted include the antibody-drug combination brentuximab vedotin, which targets CD30; checkpoint inhibitors like pembrolizumab and durvalumab; and new medicines, including CD47 inhibitor TTI-621, IL-2/IL-9/IL-15 signaling inhibitor BNZ-1, pegylated interferon alpha-2a, and anti-KIR3DL2 antibody IPH4102. Even though the early clinical trial results for these novel treatments have been positive, more extensive research is required to determine the safety and efficacy of the treatments.</p><p><strong>Conclusions: </strong>This review emphasizes the necessity for ongoing research and individualized treatment plans while highlighting the promise of these cutting-edge techniques to enhance outcomes for patients with advanced CTCL.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Postoperative Venous Thromboembolism in Patients With Gynecologic Malignancies: A Meta-analysis.","authors":"Tingting Zhang, Zhuoxia Chen, Haina Fu","doi":"10.1097/COC.0000000000001232","DOIUrl":"https://doi.org/10.1097/COC.0000000000001232","url":null,"abstract":"<p><p>To systematically evaluate the risk factors for postoperative complications of venous thromboembolism in patients with gynecologic malignancies. Cohort studies and case-control studies on the risk factors of postoperative venous thromboembolism in gynecologic malignancy patients were included in the search of China Knowledge, Wanfang, Wipro, China Biomedical Literature Database, PubMed, Cochrane Library, Embase, and Web of Science databases from inception to March 2025, and were analyzed. Studies. Data were statistically analyzed using RevMan 5.2 software. A total of 19 studies involving 123,329 patients with gynecologic malignancies were included. The analysis showed that advanced age (OR=3.08, 95% CI=2.85-3.32, P<0.00001), open surgery (OR=9.18, 95% CI=2.38-35.34, P=0.001), high surgical complexity (OR=9.97, 95% CI=5.80-17.15, P<0.00001), and surgical duration (OR=3.33, 95% CI=2.97-3.73, P<0.00001), high BMI (OR=4.77, 95% CI=3.47-6.57, P<0.00001), comorbidities (OR=21.02, 95% CI=8.72-50.70, P<0.00001), and prolonged bed rest in the postoperative period ( OR=25.16, 95% CI=10.32-61.32, P<0.00001), high intraoperative bleeding (OR=107.53, 95% CI=17.71-652.85, P<0.00001), and high D-dimer level (OR=5.55, 95% CI=3.27-9.43, P<0.00001), advanced tumor stage (OR=7.58, 95% CI=2.22-25.90, P=0.001), high tumor grade (OR=27.67, 95% CI=8.39-91.18, P<0.00001), and occurrence of lymph node metastasis (OR=31.21, 95% CI=9.54-102.15, P<0.00001) were all were risk factors for postoperative venous thrombosis in patients with gynecologic malignancies. Clinical staff should take into account the 12 risk factors identified in this study to actively identify gynecologic malignant tumor patients at high risk for venous thromboembolism after surgery and provide targeted measures to prevent or reduce the risk of postoperative DVT.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Rate and Quality of Breast Cancer Treatment Following Initial Diagnosis.","authors":"Jared Gregston, Nancy Etzold, Natalie Stratemeier, Shearwood McClelland","doi":"10.1097/COC.0000000000001229","DOIUrl":"https://doi.org/10.1097/COC.0000000000001229","url":null,"abstract":"<p><strong>Objectives: </strong>Care guidelines recommend specific treatment pathways for early-stage breast cancer, but real-world adherence may vary due to institutional workflow and system-level limitations. This study examined rates of guideline-concordant care (GCC) at a single academic medical center over 5 years and evaluated differences by stage, patient demographics and time frame involving the COVID-19 pandemic.</p><p><strong>Methods: </strong>A retrospective review was performed of all women diagnosed with American Joint Committee on Cancer (AJCC) Stage 0-III breast cancer at a National Cancer Institute-designated cancer center between September 1, 2019, and September 1, 2024. GCC was defined according to National Comprehensive Cancer Network (NCCN) guidelines as mastectomy alone, lumpectomy with radiation, or lumpectomy alone in patients ≥70. Demographic and clinical data were extracted, and rates of GCC were assessed by stage, race, insurance type, and for variance during the COVID-19 pandemic.</p><p><strong>Results: </strong>Among 1455 patients diagnosed with stage 0-III breast cancer, 981 (67.4%) received some form of treatment, and 515 (35.4%) received GCC. Stage II patients had the lowest rate of GCC (28.7%). Rates of GCC remained stable before and after April 2020, though total diagnoses declined. Black patients had the highest rate of GCC (52.1%), while Asian/Pacific Islander patients had the lowest (21.9%). No clear relationship was observed between insurance type or ZIP code-based income and GCC receipt.</p><p><strong>Conclusions: </strong>Most patients diagnosed with breast cancer received treatment, but fewer than half met criteria for GCC. Differences in GCC rate by stage and race suggest both institutional and patient-level barriers to standard care. System improvements aimed at strengthening coordination between diagnosis and treatment may help increase adherence to guideline-based breast cancer care.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}